These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30935767)
1. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus. Tomozawa T; Hoshino K; Yamashita M; Kubo S J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462 [TBL] [Abstract][Full Text] [Related]
3. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals. Kubo S; Tokumitsu A; Tomozawa T; Kakuta M; Yamashita M J Infect Chemother; 2012 Feb; 18(1):69-74. PubMed ID: 21881920 [TBL] [Abstract][Full Text] [Related]
4. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H; Kawai N Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296 [TBL] [Abstract][Full Text] [Related]
5. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors. Farrukee R; Butler J; Reading PC; Hurt AC Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385 [TBL] [Abstract][Full Text] [Related]
6. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Yamashita M Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016 [TBL] [Abstract][Full Text] [Related]
7. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. McKimm-Breschkin JL; Barrett S Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model. Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190 [TBL] [Abstract][Full Text] [Related]
9. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037 [TBL] [Abstract][Full Text] [Related]
11. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model. Farooqui A; Huang L; Wu S; Cai Y; Su M; Lin P; Chen W; Fang X; Zhang L; Liu Y; Zeng T; Paquette SG; Khan A; Kelvin AA; Kelvin DJ Antimicrob Agents Chemother; 2015 Dec; 59(12):7255-64. PubMed ID: 26369969 [TBL] [Abstract][Full Text] [Related]
13. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Kubo S; Tomozawa T; Kakuta M; Tokumitsu A; Yamashita M Antimicrob Agents Chemother; 2010 Mar; 54(3):1256-64. PubMed ID: 20047917 [TBL] [Abstract][Full Text] [Related]
14. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670 [TBL] [Abstract][Full Text] [Related]
15. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus. Fukushi M; Yamashita M; Miyoshi-Akiyama T; Kubo S; Yamamoto K; Kudo K PLoS One; 2012; 7(8):e42419. PubMed ID: 22879974 [TBL] [Abstract][Full Text] [Related]
16. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920 [TBL] [Abstract][Full Text] [Related]
18. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Hurt AC; Lowther S; Middleton D; Barr IG Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155 [TBL] [Abstract][Full Text] [Related]
19. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. Ikematsu H; Kawai N; Iwaki N; Kashiwagi S J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563 [TBL] [Abstract][Full Text] [Related]
20. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]